



1062

510(k) Summary

**Cook Biotech Incorporated  
DynaMatrix**

OCT 02 2008

## ADMINISTRATIVE INFORMATION

Manufacturer Name: Cook Biotech Incorporated  
1425 Innovation Place  
West Lafayette, Indiana 47906  
Telephone: +1 (765) 807-1942  
Fax: +1 (765) 807-7709

Official Contact: Perry W. Guinn

Representative/Consultant: David Collette, M.D.  
Floyd G. Larson  
PaxMed International, LLC  
11234 El Camino Real, Suite 200  
San Diego, CA 92130  
Telephone: +1 (858) 792-1235  
Fax: +1 (858) 792-1236  
email: dcollette@paxmed.com  
flarson@paxmed.com

## DEVICE NAME AND CLASSIFICATION

Trade/Proprietary Name: DynaMatrix™  
Common Name: Barrier, animal source, intraoral  
Classification Regulations: Class II, 21 CFR 872.3930  
Product Code: NPL  
Classification Panel: Dental Products Panel  
Reviewing Branch: Dental Devices Branch

## INTENDED USE

DynaMatrix™ is intended for use to aid in guided tissue regeneration and guided bone regeneration procedures. It may be used for bone regeneration and healing of periodontal defects, for gingival augmentation, to maintain or enhance alveolar ridges, or to contain and prevent migration of graft material. The device is provided sterile and intended for one-time use.

K082058272

## DEVICE DESCRIPTION

DynaMatrix™ is a bioabsorbable, extracellular collagen membrane matrix that is identical to the predicate SURGISIS® Periodontal Membrane (K010952), also manufactured by Cook Biotech Incorporated. This premarket notification is being submitted to expand the indications for use and to introduce a new product name.

## EQUIVALENCE TO MARKETED DEVICE

Cook Biotech Incorporated demonstrated that, for the purposes of FDA's regulation of medical devices, DynaMatrix is substantially equivalent in indications and design principles to predicate devices, each of which has been determined by FDA to be substantially equivalent to preamendment devices.



Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

OCT 02 2008

Cook Biotech, Incorporated  
C/O Dr. David J. Collette  
Regulatory Affairs  
PaxMed International, LLC  
11234 El Camino Real, Suite 200  
San Diego, California 92130

Re: K082058

Trade/Device Name: DynaMatrix™  
Regulation Number: 21 CFR 872.3930  
Regulation Name: Bone Grafting Material  
Regulatory Class: II  
Product Code: NPL  
Dated: September 26, 2008  
Received: September 29, 2008

Dear Dr. Collette:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Chiu S. Lin, Ph. D  
Division Director  
Division of Anesthesiology, General Hospital,  
Infection Control and Dental Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

1061

## Indications for Use

K082058

510(k) Number (if known): K082058

Device Name: DynaMatrix™

## Indications for Use:

DynaMatrix™ is intended for use to aid in guided tissue regeneration and guided bone regeneration procedures. It may be used for bone regeneration and healing of periodontal defects, for gingival augmentation, to maintain or enhance alveolar ridges, or to contain and prevent migration of graft material. The device is provided sterile and intended for one-time use.



(Division Sign-Off)

Division of Anesthesiology, General Hospital  
Infection Control, Dental Devices510(k) Number: K082058Prescription Use X  
(Part 21 CFR 801 Subpart D)AND/OR Over-The-Counter Use \_\_\_\_\_  
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Page 1 of 1